With a market capitalization (market cap) of $1.76B — a measure of how much the company is worth — Syndax Pharmaceuticals, Inc. is the 2195th most valuable company in Healthcare as of August 18, 2026. Shares trade at $19.92, up +0.78% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Visit websiteAs of August 18, 2026, Syndax Pharmaceuticals, Inc. (SNDX) is worth $1.76B — this is its market capitalization, the total value of all its outstanding shares.
Syndax Pharmaceuticals, Inc.’s market cap is $1.76B, which ranks it #2195 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Syndax Pharmaceuticals, Inc. (SNDX) shares trade at $19.92, up 0.78% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025